Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This article is the first of two Viewpoints on the treatment of detrusor overactivity. The authors of this article advocate the use of sacral nerve modulation for this indication, and they describe the advantages of sacral nerve modulation compared with botulinum neurotoxin.
In this second Viewpoint on the treatment of detrusor overactivity, the authors describe the preclinical and clinical data that support the use of botulinum neurotoxin in patients with detrusor overactivity, and highlight the benefits of botulinum neurotoxin over the use of sacral nerve modulation.
Despite being used in practice for around 30 years, the safety of assisted reproductive technologies is still questioned. Studies are hampered by issues related to trial design and consistency of reporting. Some long-term data are, however, now available for offspring conceived after assistance by a variety of technologies. This Review aims to summarize the reported risks.
Advances in assisted reproductive technologies have led to declining use of therapeutic donor insemination by urologists treating male factor infertility. Insemination by this technique is, however, still appropriate for a notable number of couples trying to conceive. This Review discusses the indications and the related outcomes, costs and psychosocial issues.
Recurrent prostatic bleeding can be challenging and frustrating for physicians and patients. Sepsis and bladder rupture are notable complications of therapy in severe cases, and more-serious, possibly fatal, events can occur in patients with comorbidities. An overview of causes and a guide to management with biochemical and functional approaches is provided.
Primary lymphoma of the bladder is a rare condition, typically presenting as intermittent hematuria, urinary frequency and dysuria. In this Case Study, Horasanli et al. report the management, using transurethral resection, chemotherapy and radiotherapy, of a 65-year-old woman who presented with urinary symptoms and a right hydronephrosis resulting from this tumor.
